HK1218939A1 - 用於非小細胞肺癌療法的藥物選擇 - Google Patents

用於非小細胞肺癌療法的藥物選擇

Info

Publication number
HK1218939A1
HK1218939A1 HK16106909.9A HK16106909A HK1218939A1 HK 1218939 A1 HK1218939 A1 HK 1218939A1 HK 16106909 A HK16106909 A HK 16106909A HK 1218939 A1 HK1218939 A1 HK 1218939A1
Authority
HK
Hong Kong
Prior art keywords
lung cancer
small cell
cell lung
cancer therapy
drug selection
Prior art date
Application number
HK16106909.9A
Other languages
English (en)
Inventor
Sharat Singh
Phillip Kim
Steven Lockton
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of HK1218939A1 publication Critical patent/HK1218939A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16106909.9A 2013-02-05 2016-06-15 用於非小細胞肺癌療法的藥物選擇 HK1218939A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361761105P 2013-02-05 2013-02-05
PCT/IB2014/058790 WO2014122582A1 (en) 2013-02-05 2014-02-04 Drug selection for non-small cell lung cancer therapy

Publications (1)

Publication Number Publication Date
HK1218939A1 true HK1218939A1 (zh) 2017-03-17

Family

ID=50179886

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106909.9A HK1218939A1 (zh) 2013-02-05 2016-06-15 用於非小細胞肺癌療法的藥物選擇

Country Status (4)

Country Link
US (1) US10640830B2 (zh)
EP (1) EP2954068B8 (zh)
HK (1) HK1218939A1 (zh)
WO (1) WO2014122582A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
GB201808927D0 (en) * 2018-05-31 2018-07-18 Institute Of Cancer Res Royal Cancer Hospital Materials and methods for monitoring the development of resistance of cancers to treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
ATE177842T1 (de) 1993-09-03 1999-04-15 Behringwerke Ag Fluoreszenz-sauerstoffkanalisation-immunteste
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
ES2526211T3 (es) 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
NZ616755A (en) 2009-05-14 2015-05-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
US20120270745A1 (en) 2009-07-15 2012-10-25 Prometheus Laboratories Inc. Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples
RU2558797C2 (ru) 2009-10-20 2015-08-10 Нестек С.А. Способы выявления онкогенных слитых белков, основанные на анализе близкого взаимного расположения
CN103384828A (zh) 2010-12-23 2013-11-06 雀巢产品技术援助有限公司 使用基于抗体的阵列进行恶性癌症疗法的药物选择
ES2734673T3 (es) 2011-03-02 2019-12-11 Nestle Sa Predicción de la sensibilidad farmacológica de tumores de pulmón basándose en identificaciones moleculares y genéticas
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링

Also Published As

Publication number Publication date
EP2954068B1 (en) 2018-09-05
WO2014122582A1 (en) 2014-08-14
US20160032403A1 (en) 2016-02-04
EP2954068A1 (en) 2015-12-16
US10640830B2 (en) 2020-05-05
EP2954068B8 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
IL274647A (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
SG11201605585SA (en) Targeted therapy for small cell lung cancer
GB201322725D0 (en) Cancer therapy
IL238249B (en) Cancer treatment
EP2952225A4 (en) PARTICLE BEAM THERAPY SYSTEM
HK1220900A1 (zh) 癌症的治療
EP2994148B8 (en) Cancer therapy
EP2908830A4 (en) CANCER THERAPY WITH MIRNAS
EP2994155A4 (en) Targeting the egfr-sglt1 interaction for cancer therapy
PL2831110T3 (pl) Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
EP3044593A4 (en) Cancer therapy
EP2925332A4 (en) PLACENTAL IMP THERAPY AGAINST CANCER
GB201310755D0 (en) Therapy
GB201207305D0 (en) Therapy
EP2961412A4 (en) CANCER THERAPY
DK2872176T3 (en) Cancer treatment
EP3046556A4 (en) Combination drug therapy
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
HK1218939A1 (zh) 用於非小細胞肺癌療法的藥物選擇
GB201106630D0 (en) Cancer therapy
IL245477B (en) Diagnosis of lung cancer
GB201518731D0 (en) Tumour Therapy
GB201222563D0 (en) Cancer treatment
IL239231A0 (en) Combined cancer treatment